NC State Researchers Uncover Yeast Gut Behavior for Enhanced Drug Delivery

A new study conducted by researchers at North Carolina State University offers crucial insights into the behavior of yeast cells within the gut. This foundational research aims to accelerate the development of novel yeast strains capable of more efficiently producing therapeutic drugs for a range of specific diseases.

Nathan Crook, a corresponding author and associate professor of chemical and biomolecular engineering at NC State, highlights the significant promise of this work.

"Yeast holds promise as a drug-delivery platform."

Previous studies had already indicated that modified yeast cells could produce molecules like therapeutics to reduce inflammation or combat disease directly in the gut. The current investigation specifically sought to unravel the underlying mechanisms governing gene expression and nutrient consumption in yeast within the gut environment. This understanding is vital to enhance the overall efficiency and effectiveness of yeast as drug-delivery vehicles.

Methodology

Researchers carefully selected Saccharomyces boulardii (Sb) yeast for the study. This particular species is the only one currently utilized as a probiotic, chosen due to its established safety profile.

An unmodified, off-the-shelf strain of Sb yeast was introduced into laboratory mice. Crucially, these mice were raised to be germ-free, meaning they completely lacked a gut microbiome. This germ-free environment was a strategic choice, as it simplified the identification of yeast-specific RNA without interference from other microbial genetic material.

Fecal and intestinal samples were subsequently collected from the mice. A sophisticated combination of sampling and analytical techniques was then employed to measure the RNA produced by the yeast cells during their transit through the mice's guts.

Key Findings

The study yielded several significant discoveries that could pave the way for more effective therapeutic yeast.

• Specific Genes Activated in the Gut: The research pinpointed particular genes in Sb yeast that showed significantly higher activity when in the gut environment compared to other settings. These "promoter" sections of DNA could serve as targeted on-switches to precisely control the production of therapeutic molecules by engineered yeast cells, potentially leading to improved efficiency in drug delivery.

• Safety Profile Reconfirmed: An important finding was that genes associated with potentially pathogenic behavior in the yeast were notably not activated while in the gut. This observation strongly supports the established safety profile of Sb yeast, which is already widely utilized as a probiotic.

• Nutrient Utilization Insights: Analysis of gene activation patterns revealed that the gut environment was not rich in nutrients for the yeast. Intriguingly, the yeast cells appeared to primarily digest lipids rather than carbohydrates. This suggests a promising avenue for future development: modifying yeast cells to better utilize the more complex carbohydrates abundant in the gut could significantly enhance their energy supply and, consequently, their production efficiency for therapeutic compounds.

Publication and Funding

The detailed findings of this research were published in the journal BMC Genomics under the title, 'Transcriptomic Responses of Saccharomyces boulardii to the Germ-Free Mouse Gut.'

Co-lead authors for the paper include Genan Wang and Deniz Durmusoglu, both affiliated with NC State. The authors have proactively filed patent applications and invention disclosures related to the engineering of probiotic yeast based on this work.

This groundbreaking research received crucial funding from the National Science Foundation, the Novo Nordisk Foundation, and the National Institutes of Health.